로딩 중...
52주 최고가 대비 34.0% 위치
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $154.1M | $258.2M | $426.5M | $510.2M |
| 영업이익 | - | $-39.4M | $21.6M | $139.0M | $191.4M |
| 당기순이익 | - | $-65.9M | $-28.2M | $197.7M | $146.9M |
| 잉여현금흐름 (FCF) | - | $-73.4M | $3.8M | $110.1M | $27.5M |
| 수익성 비율 | |||||
| 영업이익률 | - | -25.5% | 8.4% | 32.6% | 37.5% |
| 순이익률 | - | -42.8% | -10.9% | 46.4% | 28.8% |
| ROE (자기자본이익률) | - | -43.4% | -20.9% | 56.6% | 30.8% |
| ROA (자산이익률) | - | -18.9% | -8.6% | 40.5% | 23.5% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 67.6% | 65.2% | 19.6% |
| EPS 성장률 (YoY) | - | 35.3% | 60.6% | 723.1% | - |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | 19.9x | - |
| PBR (주가순자산배수) | - | 5.6x | 8.9x | 10.7x | 8.4x |
| PSR (주가매출배수) | - | 5.6x | 4.7x | 8.8x | 7.9x |
| FCF Yield | - | -8.6% | 0.3% | 2.9% | 0.7% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 1.02 | 1.05 | 0.24 | 0.17 |
| 유동비율 | - | 6.89 | 5.16 | 5.97 | 6.71 |
MOLINA HEALTHCARE INC
$179.86
$9.4B